World Journal of Gastrointestinal Oncology最新文献

{"title":"Endothelial Per-Arnt-Sim domain-containing protein 1 expression is correlated with poor prognosis and promotes invasion and metastasis in gastric cancer.","authors":"Wang Xu, Wang Li, Jia Ru","doi":"10.4251/wjgo.v17.i6.105213","DOIUrl":"10.4251/wjgo.v17.i6.105213","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Hypoxia, which is common in solid tumors, contributes to tumor progression. <i>EPAS1</i>, also known as <i>HIF2-α</i>, is a key regulator of cellular responses to hypoxia and is implicated in carcinogenesis. While less studied than <i>HIF1-α</i> is, <i>EPAS1</i> is overexpressed in various cancers, including GC.</p><p><strong>Aim: </strong>To assess the relationship between <i>EPAS1</i> expression and prognosis in GC and investigate its possible role in the development of GC.</p><p><strong>Methods: </strong><i>EPAS1</i> expression in GC and adjacent tissues was assessed using immunohistochemistry. Correlations with clinicopathological features were analyzed by using The Cancer Genome Atlas (TCGA) and clinical data to evaluate its prognostic value. The TIMER2.0 database was used to examine associations between <i>EPAS1</i> and immune-infiltrating cells. Gene set enrichment analysis identified the mechanisms underlying the role of <i>EPAS1</i> in GC progression. The relationships between <i>EPAS1</i> and immunological checkpoints were analyzed in the TCGA-STAD cohort. Cell and animal experiments confirmed the role of <i>EPAS1</i> in invasion and metastasis.</p><p><strong>Results: </strong><i>EPAS1</i> expression was significantly greater in GC tissues than in adjacent tissues (<i>P</i> < 0.05). High <i>EPAS1</i> expression was correlated with shorter overall survival (OS) and was associated with greater infiltration depth and poorer tumor differentiation (<i>P</i> < 0.05). Univariate and multivariate Cox analyses revealed that <i>EPAS1</i> expression (HR: 2.095; 95%CI: 1.019-4.307; <i>P</i> < 0.001) was an independent predictor of OS. <i>EPAS1</i> was enriched in the epithelial-mesenchymal transition (EMT), inflammatory response, KRAS, TGF-β, TNF-/NF-kB, and IL6/JAK/STAT3 signaling pathways. The high <i>EPAS1</i> expression group presented increased levels of pathway-related molecules and immunotherapy checkpoints. <i>In vitro</i> and <i>in vivo</i> studies confirmed that silencing <i>EPAS1</i> reduced GC cell invasion and metastasis.</p><p><strong>Conclusion: </strong><i>EPAS1</i> may be a prognostic marker in patients with GC and may promote tumor growth through the immune response and pathways associated with EMT, inflammatory response, KRAS, TGF-β, TNF-/NF-kB, and IL6/JAK/STAT3 signaling.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105213"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and validation of extracellular matrix-related genes in the progression of gastric cancer with intestinal metaplasia.","authors":"Lu Wang, Meng-Han Wang, Yao-Hong Yuan, Rui-Ze Xu, Lu Bai, Mi-Zhu Wang","doi":"10.4251/wjgo.v17.i6.105160","DOIUrl":"10.4251/wjgo.v17.i6.105160","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is a highly lethal malignancy with a high incidence and mortality rate globally. Its development follows the Correa model, with intestinal metaplasia (IM) being a critical precursor to GC. However, the mechanisms underlying IM progression to GC remain unclear. This study explored extracellular matrix (ECM)-related gene changes during IM progression to GC, aiming to identify biomarkers that could improve early diagnosis and treatment strategies for GC, ultimately enhancing patient outcomes.</p><p><strong>Aim: </strong>To analyze transcriptome sequencing data, molecular biomarkers that can predict GC risk and monitor IM progression can be identified, providing new insights and strategies for preventing IM-GC transformation.</p><p><strong>Methods: </strong>Weighted gene co-expression network analysis served for confirming gene modules. Upregulated ECM-related genes were further tested using univariate Cox regression and least absolute shrinkage and selection operator analysis to select hub genes and construct a survival analysis model. The intestinal cell model was established by stimulating GES-1 cells with chenodeoxycholic acid.</p><p><strong>Results: </strong>Weighted gene co-expression network analysis identified 1709 differentially expressed genes from the GSE191275 dataset, while The Cancer Genome Atlas stomach adenocarcinoma revealed 4633 differentially expressed genes. The intersection of these datasets identified 71 upregulated and 171 downregulated genes, which were enriched in ECM-related pathways. Univariate Cox regression analysis identified six genes with prognostic significance, and least absolute shrinkage and selection operator regression pinpointed secreted protein acidic and rich in cysteine <i>(SPARC)</i> and <i>SERPINE1</i> as non-zero coefficient genes. A prognostic model integrating clinical tumor node metastasis staging, age, <i>SERPINE1</i>, and <i>SPARC</i> was constructed. Immunohistochemistry analysis confirmed an increasing expression of SPARC protein from normal gastric mucosa (-), to IM (+- to +), and to GC (+ to ++), with significant differences (<i>P</i> < 0.05). Western blot analysis demonstrated significantly higher SPARC expression in induced intestinal cells compared to GES-1. Furthermore, after <i>SPARC</i> knockdown in the human GC cell line HGC27, cell counting kit-8 and colony formation assays showed a reduction in cell proliferative ability, while the wound healing assay revealed impaired cell migration capacity.</p><p><strong>Conclusion: </strong>Comprehensive analysis suggested that a model incorporating clinical tumor node metastasis staging, age, and <i>SPARC</i>/<i>SERPINE1</i> expression served as a prognostic predictor for GC. Moreover, elevated SPARC expression in IM and GC suggests its potential as a proper biomarker to detect GC in early stage and as a novel therapeutic target, guiding clinical applications.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105160"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative model for predicting early recurrence in hepatocellular carcinoma patients using radiomics and deep learning: A multicenter study.","authors":"Yong-Hai Li, Gui-Xiang Qian, Ling Yao, Xue-Di Lei, Yu Zhu, Lei Tang, Zi-Ling Xu, Xiang-Yi Bu, Ming-Tong Wei, Jian-Lin Lu, Wei-Dong Jia","doi":"10.4251/wjgo.v17.i6.106608","DOIUrl":"10.4251/wjgo.v17.i6.106608","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Ablation therapy is one of the first-line treatments for early HCC. Accurately predicting early recurrence (ER) is crucial for making precise treatment plans and improving patient prognosis.</p><p><strong>Aim: </strong>To establish an intratumoral and peritumoral model for predicting ER in HCC patients following curative ablation.</p><p><strong>Methods: </strong>This study included a total of 288 patients from three Centers. The patients were divided into a primary cohort (<i>n</i> = 222) and an external cohort (<i>n</i> = 66). Radiomics and deep learning methods were combined for feature extraction, and models were constructed following a three-step feature selection process. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), while calibration curves and decision curve analysis (DCA) were used to assess calibration and clinical utility. Finally, Kaplan-Meier (K-M) analysis was used to stratify patients according to progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>The combined model, which utilizes the light gradient boosting machine learning algorithm and incorporates both intratumoral and peritumoral regions (5 mm and 10 mm), demonstrated the best predictive performance for ER following HCC ablation, achieving AUCs of 0.924 in the training set, 0.899 in the internal validation set, and 0.839 in the external validation set. Calibration and DCA curves confirmed strong calibration and clinical utility, whereas K-M curves provided risk stratification for PFS and OS in HCC patients.</p><p><strong>Conclusion: </strong>The most efficient model integrated the tumor region with the peritumoral 5 mm and 10 mm regions. This model provides a noninvasive, effective, and reliable method for predicting ER after curative ablation of HCC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"106608"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in the study of therapeutic strategies for hepatoblastoma in children.","authors":"Ran Tang, Shi-Qin Qi, Tao Zhang, Zhu-Bin Pan, Jia-Hua Xu","doi":"10.4251/wjgo.v17.i6.107700","DOIUrl":"10.4251/wjgo.v17.i6.107700","url":null,"abstract":"<p><p>Hepatoblastoma (HB) is the most common primary malignant liver tumor in children, representing approximately 50% to 60% of pediatric liver cancers. It predominantly affects children under the age of 3 years, with a slightly higher incidence in boys compared to girls. The main pathological subtypes of HB are epithelial and mixed types. The etiology and pathogenesis are unclear and may be related to factors such as genetics and gene mutations. The diagnosis primarily relies on imaging examinations (including abdominal ultrasound, computed tomography, and magnetic resonance imaging) and serum alpha-fetoprotein testing. Treatment approaches include surgical resection, chemotherapy, and liver transplantation. Surgical resection is currently the only curative option, especially effective for early-stage localized tumors; chemotherapy can be used to shrink tumors before surgery or to manage their progression; liver transplantation is recommended for cases that cannot be surgically removed or for instances where the disease recurs after surgery. Recent advancements have encouraged a multidisciplinary approach to treatment, with ongoing research into new chemotherapeutic and targeted agents. Despite these developments, challenges remain, such as the need for more precise and individualized therapies, chemotherapy resistance that can lead to poor outcomes in some patients, and a shortage of organ donors, along with the risk of immune rejection after transplantation. A thorough synthesis of current therapeutic strategies will establish an evidence-based foundation to enhance the management of HB in children, ultimately improving prognosis and quality of life.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"107700"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of myosin heavy chain 9 in gastrointestinal tumorigenesis: A comprehensive review.","authors":"Xue-Fan Zeng, Yi-Wei Wang, Yao Ou, Ling Liu","doi":"10.4251/wjgo.v17.i6.106617","DOIUrl":"10.4251/wjgo.v17.i6.106617","url":null,"abstract":"<p><p>Myosin heavy chain 9 (MYH9), a non-muscle myosin heavy chain protein, has been identified as a significant factor in gastrointestinal (GI) oncology, with its overexpression in various GI malignancies such as esophageal, gastric, and colorectal cancers being associated with poor prognosis and playing a role in tumor invasion and metastasis. This comprehensive review synthesizes the current body of knowledge regarding MYH9's role in GI tumors, focusing on its molecular mechanisms, including its interaction with key signaling pathways like the phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin axis, which suggests a role in cancer cell survival, proliferation, and epithelial-mesenchymal transition. The review also explores MYH9's potential as a therapeutic target, with preclinical models demonstrating promising results in inhibiting tumor growth and enhancing chemosensitivity. The evidence suggests that MYH9 is a multifaceted protein with significant implications in GI tumor biology, warranting further research to elucidate its mechanisms of action and develop targeted therapies that could improve patient outcomes.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"106617"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor-derived exosomal miR-425-5p and miR-135b-3p enhance colorectal cancer progression through immune suppression and vascular permeability promotion.","authors":"Chun-Zai Feng, Si-Quan Zhong, Shao-Wei Ye, Zheng Zheng, Hao Sun, Shi-Hai Zhou","doi":"10.4251/wjgo.v17.i6.106161","DOIUrl":"10.4251/wjgo.v17.i6.106161","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality globally. Exosomal microRNAs (miRNAs) are known to modulate tumor progression by influencing immune responses and vascular dynamics. However, the roles of specific exosomal miRNAs, such as miR-425-5p and miR-135b-3p, in CRC remain unclear.</p><p><strong>Aim: </strong>To explore the specific roles and underlying mechanisms of exosomal miR-425-5p and miR-135b-3p in CRC progression.</p><p><strong>Methods: </strong>Differentially expressed miRNAs were identified through microarray analysis of exosomes isolated from CRC tissues and adjacent normal mucosa. Functional roles of miR-425-5p and miR-135b-3p were evaluated <i>in vitro</i> using macrophage polarization, T cell differentiation, and vascular permeability assays, as well as <i>in vivo</i> tumor formation and metastasis experiments in nude mice. Validation experiments were performed using CRC cell lines (HCT116 and SW620).</p><p><strong>Results: </strong>Exosomal miR-425-5p and miR-135b-3p were significantly upregulated in CRC compared to normal tissues. Functional studies revealed that miR-425-5p promotes macrophage M2-like polarization and suppresses T cell proinflammatory responses, while miR-135b-3p enhances vascular permeability and angiogenesis. Inhibition of these miRNAs in CRC cell-derived exosomes significantly suppressed tumor growth and metastasis in nude mice, reprogramming the tumor microenvironment toward reduced angiogenesis and enhanced immune activation. Combined inhibition of both miRNAs resulted in the most pronounced effects.</p><p><strong>Conclusion: </strong>Exosomal miR-425-5p and miR-135b-3p drive CRC progression by promoting immune suppression and vascular permeability. Their inhibition offers a promising strategy for modulating the tumor microenvironment and limiting CRC metastasis.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"106161"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the potential of plasma DNA methylation in the detection and surveillance of esophageal cancer.","authors":"Jitesh Arora, Mahmoud Nassar, Bahaaeldin Baraka","doi":"10.4251/wjgo.v17.i6.103333","DOIUrl":"10.4251/wjgo.v17.i6.103333","url":null,"abstract":"<p><p>Esophageal cancer (EC) continues to pose a significant clinical challenge due to the absence of a reliable early detection method, leading to late-stage diagnoses and poor patient outcomes. The recent study by Liu <i>et al</i> presents a promising breakthrough, demonstrating that plasma DNA methylation markers-SHOX2, SEPTIN9, EPO, and RNF180-offer a non-invasive approach for early EC detection with 76.19% sensitivity and 86.27% specificity. Given the urgent need for effective screening strategies, the potential integration of this assay into clinical practice could significantly enhance early diagnosis, patient monitoring, and overall survival rates. While further validation is necessary, this advancement marks an important step toward improving EC detection and management.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"103333"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling genetic susceptibility in esophageal squamous cell carcinoma and revolutionizing pancreatic cancer diagnosis through imaging.","authors":"Sheng-Ke Zhang, Lai Jiang, Cheng-Lu Jiang, Qiang Cao, Yu-Quan Chen, Hao Chi","doi":"10.4251/wjgo.v17.i6.102544","DOIUrl":"10.4251/wjgo.v17.i6.102544","url":null,"abstract":"<p><p>Two landmark studies demonstrate synergistic approaches to gastrointestinal cancer management. Lin <i>et al</i> identified activin A receptor type 1C polymorphisms (rs4556933/rs77886248) as esophageal squamous cell carcinoma risk modifiers in Chinese Han populations through a case-control study (1264 patients/1361 controls), revealing transforming growth factor-beta pathway-mediated susceptibility in older male smokers (<i>P</i> < 0.001). Concurrently, Luo <i>et al</i> established imaging-based differentiation of pancreatic cancer subtypes (pancreatic ductal adenocarcinoma <i>vs</i> neuroendocrine tumors) <i>via</i> retrospective analysis of 500 cases (area under the curve = 0.89), enabling earlier intervention. These findings underscore the transformative potential of combining genetic risk stratification with advanced imaging to guide precision screening and therapeutic strategies, addressing critical gaps in esophageal and pancreatic cancer outcomes.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"102544"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of serum S100A12, soluble advanced glycation end products receptor, and gut microbiome in elderly patients with colorectal cancer.","authors":"Shuai-Bo Qiao, Ming-Liao Niu, Wei-Tao Liang, Long-Jiang Zhang, Xiang Chen, Ying-Kun Zhu","doi":"10.4251/wjgo.v17.i6.106393","DOIUrl":"10.4251/wjgo.v17.i6.106393","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Colorectal cancer (CRC) ranks among the most prevalent malignancies in elderly populations, and chemotherapy resistance remains a critical clinical challenge. Emerging evidence highlights the interplay between chronic inflammation, gut microbiome dysbiosis, and CRC progression. Proinflammatory cytokines [&lt;i&gt;e.g.&lt;/i&gt;, interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α)] and mediators like S100 calcium-binding protein A12 (S100A12)/soluble receptor for advanced glycation end products (sRAGE) are implicated in tumorigenesis, while gut microbial imbalances may exacerbate inflammatory microenvironments conducive to chemotherapy resistance. However, the triad relationship between S100A12/sRAGE, gut microbiota profiles, and chemotherapy efficacy in elderly patients with CRC remains unexplored, limiting biomarker-driven therapeutic strategies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To analyze the correlation between serum levels of S100A12, sRAGE, gut microbiome dysbiosis, and systemic inflammation in elderly patients with CRC and to assess their predictive value for chemotherapy efficacy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was conducted on the clinical data of 120 elderly patients with advanced-stage CRC who visited our hospital from August 2023 to May 2024. These patients were enrolled in the study group. Additionally, 120 healthy individuals undergoing routine health check-ups during the same period were selected as the control group. Serum S100A12, sRAGE, IL-6, and TNF-α levels were measured by ELISA, and fresh stool samples were collected before chemotherapy to analyze gut microbiome composition in the study group. Follow-up observations were conducted after chemotherapy. Pearson correlation analysis was used to explore the relationship between serum S100A12, sRAGE levels, and gut microbiome dysbiosis in patients with CRC. The predictive diagnostic value of pre-chemotherapy serum S100A12 and sRAGE levels for chemotherapy efficacy was assessed using receiver operating characteristic curves.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Pre-chemotherapy serum S100A12, sRAGE, IL-6, and TNF-α levels were significantly elevated in patients with CRC &lt;i&gt;vs&lt;/i&gt; controls (all &lt;i&gt;P&lt;/i&gt; &lt; 0.05). These biomarkers progressively increased with microbiota dysbiosis severity (severe &lt;i&gt;vs&lt;/i&gt; mild dysbiosis: S100A12: 340.26 ± 52.39 μg/L &lt;i&gt;vs&lt;/i&gt; 302.53 ± 56.97 μg/L; sRAGE: 525.64 ± 37.32 ng/L &lt;i&gt;vs&lt;/i&gt; 441.38 ± 48.73 ng/L, &lt;i&gt;P&lt;/i&gt; &lt; 0.05) and correlated strongly with IL-6 (&lt;i&gt;r&lt;/i&gt; = 0.712) and TNF-α (&lt;i&gt;r&lt;/i&gt; = 0.698). Post-chemotherapy, biomarker levels decreased (&lt;i&gt;P&lt;/i&gt; &lt; 0.05), coinciding with beneficial microbiota recovery (&lt;i&gt;Bifidobacterium&lt;/i&gt; 176%, &lt;i&gt;Lactobacillus&lt;/i&gt; 153%) and pathogenic taxa reduction (&lt;i&gt;Escherichia coli&lt;/i&gt; 62%). The combined S100A12/sRAGE model predicted chemotherapy resistance with an area under the curve of 0.914 (sensitivity = 86.07%, specificity = 88.89%), outperforming individual biomarkers.&lt;","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"106393"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global scientific trends on hepatocellular carcinoma research from 2004 to 2023: A bibliometric and visualized analysis.","authors":"Li-Qi Shang, Hao-Xin Guo, Peng Wang, Xiao-Han Sun, Jia-Qi You, Jun-Ting Ma, Lu-Ke Wang, Jia-Xi Liu, Zhong-Qing Wang, Hai-Bo Shao","doi":"10.4251/wjgo.v17.i6.105781","DOIUrl":"10.4251/wjgo.v17.i6.105781","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide, and the research landscape has rapidly evolved over the past two decades. Despite significant progress, an in-depth analysis of global research trends, collaborative networks, and emerging themes in HCC remains limited. This study aimed to fill this gap by conducting a bibliometric analysis to map the research output, identify key contributors, and highlight future directions in HCC research. We hypothesized that the analysis would reveal a growing focus on molecular mechanisms and immunotherapy, with increasing contributions from specific countries and institutions.</p><p><strong>Aim: </strong>To investigate global research trends, collaborative networks, and emerging themes in HCC from 2004 to 2023.</p><p><strong>Methods: </strong>A bibliometric analysis was performed using 93987 publications from the Science Citation Index Expanded Database of the Web of Science Core Collection. Data were analyzed using the VOSviewer software to identify publication trends, leading contributors, and research themes. Key metrics included annual publication output, country and institutional contributions, journal impact, and thematic clusters. Statistical analysis was carried out to quantify trends and collaborations.</p><p><strong>Results: </strong>The number of annual publications increased from 2341 in 2004 to 8756 in 2023, with 65583 papers (69.78%) published between 2014 and 2023. China, the United States, and Japan were the top contributors, constituting 58.3% of total publications. <i>PLOS One</i> published the most studies (<i>n</i> = 2145), while <i>Gastroenterology</i> had the highest average number of citations (78.4 citations per paper). Fudan University was the most prolific institution (<i>n</i> = 1872). Thematic analysis identified five main clusters, namely molecular mechanisms, therapeutic strategies, prognosis and immunology, risk factors, and diagnostic approaches.</p><p><strong>Conclusion: </strong>This study highlights the growing focus on HCC research, particularly in immunotherapy and molecular mechanisms, underscoring the significance of international collaboration to advance diagnosis and treatment strategies.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 6","pages":"105781"},"PeriodicalIF":2.5,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}